MONOCLONAL ANTIBODIES IN IMMUNODIAGNOSIS AND IMMUNOTHERAPY Volume 34, Number 3, 2015 ª Mary Ann Liebert, Inc. DOI: 10.1089/mab.2014.0088

Monoclonal Antibodies Against Human Cardiac Troponin I for Immunoassays II Gregory Lee and Suefay Liu

Human cardiac troponin I (cTnI) is one of the most specific biomarkers for detection of acute myocardial infarction (AMI). To formulate immunoassay kits for rapid immunodiagnosis of AMI, monoclonal antibodies with high affinity and specificity were generated against cTnI and subsequently tested through a series of experiments. C57BL/6 mice were immunized with cTnI as the immunogen and cell fusions with myeloma cells of BALB/c origin were performed to generate hybridomas. The supernatants of the hybridoma cell culture were routinely screened for antibody secretions against intact cTnI and synthetic peptides from the N-terminal half of cTnI (amino acid residues N1-30, N24-40, N59-79, and N80-95). Monoclonal antibodies specific to different epitope regions were then determined and selected, according to their respective affinity and specificity, for formulation of enzyme immunoassay kits. The results of this study found that most of the selected antibodies revealed comparable binding affinity to cTnI and to the corresponding synthetic peptides. Optimal sandwich enzyme immunoassays with high sensitivity could be achieved through proper combinations of the epitopedistinct monoclonal antibodies in different capture-detection pairs; signal enhancements were frequently observed when a mixture of epitope-distinct anti-cTnI monoclonal antibodies was used for coating. This indicates that a combination of epitope-distinct anti-cTnI monoclonal antibodies recognizing the N-terminal half of cTnI yield reliable detection and greater sensitivity for cTnI in AMI patients.



roponin I is a subunit of the troponin complex that is involved in the regulation of skeletal and cardiac muscle contraction. In humans, three different isoforms of troponin I are expressed with separate isoforms presenting in fast-twitch skeletal muscle, slow-twitch skeletal muscle, and cardiac muscle. The cardiac isoform of troponin I, human cardiac troponin I (cTnI), is expressed exclusively in the heart tissue and differs from skeletal isoforms by about 40% in amino acid sequence.(1) In addition, cTnI contains 31 unique amino acid residues in its N-terminus.(2) Because of the tissue-specific expression of cTnI in the heart tissue, cTnI has been utilized as a marker for cardiac damage. For the past two decades, cTnI has been established as one of the most specific biomarkers for diagnosis of acute myocardial infarction (AMI).(3) In normal healthy patients, levels of cTnI are very low, while in AMI patients, cTnI levels are elevated. Therefore, cTnI is widely used in the clinical setting for differential diagnosis of patients presenting with chest pain.(4) Early detection of higher than normal levels of cTnI in the bloodstream and diagnosis of AMI are necessary in order to guide time-sensitive decisions in patient management and to decrease the number of missed AMI cases.

Given the urgent need for a highly sensitive cTnI assay for early detection of AMI, antibodies of high affinity and specificity are desirable for the formulations of rapid and sensitive immunoassays. However, complications arise from the instability of cTnI in the human circulation following AMI onset.(5–10) It is generally accepted that cTnI released from the cardiac muscle exists primarily in complex with troponin C (TnC) and troponin T (TnT), together known as the ITC complex, as well as in high degrees of heterogeneity in the human blood.(6) Purified cTnI is highly susceptible to proteolytic degradation, but within the ITC complex the central part of cTnI is protected from proteolysis due to the binding of TnC. Therefore, the most stable part of cTnI is located between amino acid residues 30 and 110.(5) Furthermore, lack of conformational stability of matrix cTnI in the ITC complex results in the generation of monoclonal antibodies reacting with mainly the linear epitopes of Nterminal half (N1-110) of cTnI. In view of our current understanding of the specificity of cTnI, early detection of cTnI in the human blood by highly sensitive immunoassays allow the identification of AMI patients within the first 1–3 h, thus making cTnI an early marker of AMI.(11,12) In this communication, anti-cTnI monoclonal antibodies of high affinity and specificity were generated and

UBC Center for Reproductive Health, Vancouver, British Columbia, Canada.



their epitopes mapped to formulate immunoassays for reliable and sensitive clinical detection of cTnI among AMI patients. Materials and Methods Chemicals

Unless otherwise specified, all chemicals and reagents were obtained from Sigma Chemical Co. (St. Louis, MO). Clinical specimens

Most of the frozen clinical serum specimens from the normal non-AMI control and AMI patients were provided by Lake Arrowhead Laboratory Consultants (Blue Jay, CA). Minor clinical patient serum specimens were obtained from the Department of Cardiology at the Vancouver General Hospital (Canada). Troponin I isoforms and synthetic peptides

Purified cTnI (free form) and other cTnI isoforms were obtained from Scripps Laboratories (San Diego, CA). Purified troponin I-T-C complex was purchased from BiosPacific (Emeryville, CA). Oligopeptides corresponding to different parts of cTnI amino acids (N1-30, N24-40, N59-79, and N80-95) were synthesized by GenScript (Piscataway, NJ). Production of monoclonal antibodies to human cardiac troponin I

A preliminary report for the generation and production of monoclonal antibodies against cTnI has been published previously.(13) Basically, more monoclonal antibodies were generated by using the same methodology with minor mod-


ifications and improvement. The emphasis is placed on the identification of high affinity monoclonal antibodies reacting with epitopes specifically in the N-terminal half of cTnI. These monoclonal antibodies were mapped by using specific synthetic peptides of cTnI located in the N-terminal half of cTnI (N1-30, N24-40, N59-79, and N80-95) (see Fig. 1). For final formulations of enzyme immunoassay kits to achieve desirable assay sensitivity, various mixtures of epitope-distinct monoclonal antibodies were selected for capturing and signal detections (described in the Results section). Enzyme immunoassays were performed by using standard protocols, as described previously. cTnI standards from human heart extract were calibrated against the kit obtained from HyTest (Turku, Finland). Results Generation and characterization of monoclonal antibodies against distinct epitopes of human cardiac troponin I

Based on previous experience in our laboratory, C57BL/6 mice were used for immunizations with cTnI followed by cell fusions with myeloma cells of BALB/c origin.(13,14) This resulted in a higher immune response and higher yields of anticTnI positive hybridomas. Therefore, more than ten cycles of cell fusion experiments were performed with thousands of hybridomas generated and routinely screened for secretion of anti-cTnI monoclonal antibodies. Special attention was paid to those that reacted with synthetic peptides (N1-30, N24-40, and N80-95) derived from the N-terminal half (N1-110) of cTnI molecules. Based on their respective epitope specificity, a group of anti-troponin I monoclonal antibodies were identified and are listed in Table 1. The relative epitope locations recognized by

FIG. 1. Epitope locations recognized by the generated monoclonal antibodies for human cardiac troponin I (N1-110). N24-40A and N24-40B are two distinct epitopes recognized by two separate monoclonal antibodies. Same observations were made with those of N59-79A and N59-79B.


Table 1. Monoclonal Antibodies Specific to Different Epitope Regions of N-Terminal Half of cTnI and Relative Dissociation Constants Monoclonal antibodies PC1 PC3 PC4 TPC101 TPC110 TPC213 TPC104 TPC108 TPC201 TPC206 TPC413 TPC417 TPC117 TP8 TP115 TP106 TP108

Relative epitope regions of cTnIa

Relative dissociation constants

N1-30 N1-30 N1-30 N24-40A N24-40A N24-40B N24-40 N24-40 N24-40 N24-40 N59-79A N59-79B N80-95 TBD TBD TBD TBD

ND ‡ 10 nM ND 0.45 nM 0.37 nM 0.76 nM ND ND ND ND 0.39 nM 0.40 M 1.9 nM ‡ 10 nM ‡ 10 nM ND ND

a N24-40A and N24-40B are two distinct epitopes recognized by two separate monoclonal antibodies. The same observations were made with those of N59-79A and N59-79B. ND, not determined; TBD; to be determined.

these monoclonal antibodies are also presented for comparisons. Some were shown to recognize amino acid residues N1-30 of cTnI (PC1, PC3, and PC4). Seven were specific to the epitopes located on the N24-40 peptide, while the other two recognized the N59-79 peptide, and one reacted with the epitope region on the N80-95 peptides. The epitope regions of the remaining four have not yet been unambiguously assigned. Cross-reactivity between the selected monoclonal antibodies and two of the TnI isoforms from fast twitch and slow twitch skeletal muscle were also examined through typical binding ELISA.(15) It was clearly demonstrated that the selected monoclonal antibodies specific to these selected N-terminal half epitope regions displayed little cross-reactivity to any of these two skeletal muscle TnI isoforms. Therefore, all were considered to be highly specific to cTnI. Relative dissociation constants of some of these monoclonal antibodies to cTnI were determined through typical binding assays with micro-wells coated with cTnI antigen derived from human heart extract. The dissociation constants of selected high affinity monoclonal antibodies were estimated and are presented in Table 1 for comparative purposes. Among the selected antibodies, the dissociation constants (Kd) range from 0.37 nM for TPC110 to 1.9 nM for TPC117. The relative affinities of the selected monoclonal antibodies to cTnI were found to be slightly better than those from commercial sources. For example, under our routine assay conditions, HyTest 9C17 and 8E10 were shown to have Kds of 1.8 nM and 8.6 nM, respectively. On the other hand, Medix 9701, 9703, 9705, and 9707 have Kds ranging from 1.3 to 4.3 nM. By means of competitive binding experiments, the relative pairings between any two monoclonal antibodies can be as-


Table 2. Antibody Pair Recommendations for Quantitative cTnI Sandwich Immunoassays Assay typea 1+1 1+1 2+1 2+1 3+1

TPC117 TPC213 TPC117 + TPC417 TPC117 + TPC213 TPC117 + TPC213 + TPC413 TPC117 + TPC213 + TPC 413 + TPC417

4+1 a

Capturing antibody

Detecting antibody TPC110 TPC110 TPC110 TPC110 TPC110

or or or or or

TPC101 TPC101 TPC101 TPC101 TPC101

TPC110 or TPC101

Typical assay conditions are described in text.

sessed. As described in Table 1, two distinct epitopes exist in either the N24-40 or N59-79 synthetic peptides as each peptide can be recognized by two separate monoclonal antibodies. Therefore, the binding signals can be enhanced when both epitope-distinct antibodies in the same epitope region are paired. They can also pair simultaneously with a third antibody located in other epitope regions. For example, TPC101 (N24-40A) or TPC110 (N24-40A) can be paired with TPC213 (N24-40B) for sandwich immunoassay. Similarly, TPC413 (N59-79A) and TPC417 (N59-79B) can be mutually paired. The relative locations of these distinct epitopes recognized by the selected monoclonal antibodies along the N-terminal half of cTnI amino acid sequences were determined and are presented diagrammatically in Figure 1. Since TPC101 and TPC110 have relatively high affinity to cTnI, either one can be conjugated with HRP for signal detection in a sandwich enzyme immunoassay. For capturing cTnI, the micro-wells can be coated with one to four epitopedistinct monoclonal antibodies to increase the assay sensitivity. Based on this assumption, proper combinations of the selected anti-cTnI monoclonal antibodies can result in the desirable assay sensitivity for early detection of AMI patients. The results of such pairing combinations are listed in Table 2. During pairing experiments with various mixtures of epitope-distinct anti-troponin I monoclonal antibodies, it was noted that signal enhancement was obtained upon combinations of two or more antibodies in a typical sandwich enzyme immunoassay. Results of such examples are shown in Table 3. When TPC417 was mixed equally with TPC117, TPC213,

Table 3. Signal Enhancements with Mixed Antibody Coated Wells

TPC117 TPC213 TPC413 TPC417






1.242 [0.746]

2.479 2.147 [1.745]

0.777 1.419 2.218 [0.061]

Wells were coated with 10 mg/mL of each antibody indicated on x and y axes. Values given are those achieved with 3.3 ng/mL of cTnI following 30 min co-incubation at 37C with horseradish peroxidase-labeled TPC101 and subtraction of the blank. Numbers in brackets ([ ]) designate values obtained from well coating with 10 mg/mL of a given antibody and 10 mg/mL of normal mouse IgG.



FIG. 2. Typical standard curve of cTnI with a mix of TPC117, TPC213, and TPC413 as the capturing antibody and TPC101 as the detection antibody. Wells were coated with 20 mg/mL total of TPC117, TPC213, and TPC413. Serial dilution of cTnI was performed with 30 min coincubation at room temperature horseradish peroxidaselabeled TPC101. or TPC413, significant signal enhancement was observed in each case. Judging from such analyses, an assay sensitivity of 0.10– 0.15 ng/mL cTnI can be achieved by a typical enzyme immunoassay within 30–45 min of total incubation time at room temperature. A typical standard curve of this sandwich enzyme immunoassay is presented in Figure 2. Clinical correlation studies

A combination of three epitope-distinct monoclonal antibodies (TPC117, TPC213, and TPC413) was used for coating as capturing antibodies on micro-wells. TPC110-HRP served as the detecting antibody. A typical sandwich enzyme immunoassay was employed to perform clinical correlation studies. The results are summarized and presented in Table 4. From these clinical correlation studies, it is clearly demonstrated that the assay results of the EIA kit formulated in this study are well correlated with those of Abbott’s AxSYM, with correlation coefficients of 0.9018 for AMI cases and 0.8036 for non-AMI cases, respectively. Discussion

According to the American Heart and Stroke Association, the estimated annual incidence of AMI in the USA in 2014 was 515,000 for new attacks and 205,000 for recurrent events. In addition, approximately 15% of patients, who experienced an AMI, died.(16) Therefore, early detection of

Table 4. Clinical Correlations of Formulated Enzyme Immunoassay Kit with That of AxSYM System Based on Results from AMI Cases Total number of AMI cases Mean from AxSYM system Mean from present study Correlation coefficient Slope Intercept

n = 110 18.14 ng/mL 18.26 ng/mL 0.9018 0.9001 0.3405

AMI is crucial in order to guide quick medical treatment and intervention to AMI patients and prevent complications arising from AMI and patient death. Highly sensitive cTnI assays can aid in detecting AMI patients within 1–3 h after AMI onset and ensure prompt and accurate medical care. In this study, a variety of anti-cTnI monoclonal antibodies were generated and selected. Our final selection of these antibodies was based on the assumption that the N-terminal half of cTnI is the most stable part of cTnI in human blood.(5,13) Other cTnI assays that have demonstrated superior clinical performance, such as Beckman Coulter’s AccuTnI assay, also utilize monoclonal antibodies with epitopes in this region.(17) It is known that cTnI in human blood exists predominantly in a complex form with TnC and TnT, and does not have a stable and well-defined tertiary or conformational structure in the ITC complex.(6) Therefore, it is possible to identify more epitope-distinct monoclonal antibodies for cTnI than for other globular proteins that possess limited accessible epitopes. It was also found that mutual pairings of anti-cTnI monoclonal antibodies in a sandwich enzyme immunoassay are possible when a pair of epitope-distinct monoclonal antibodies was used in the assay format. Furthermore, assay sensitivity can also be enhanced through a proper combination of epitope-distinct monoclonal antibodies, due to cooperative binding of the antibody mixture to the analyte.(18) Examples of such signal enhancement experiments can even be demonstrated with a mixed coating of two monoclonal antibodies, as demonstrated in Table 3. Therefore, the immunoassays can be performed with a combination of more than two mutually epitope-distinct monoclonal antibodies in order to achieve high assay sensitivity. The different epitope specificity of the monoclonal antibodies for cTnI may also play a role in determining clinical performance of the assay.(17) In view of the fact that TPC110 shows one of the highest affinities to cTnI, it has been widely used by a number of major immunodiagnostics companies since 1999 as one of the key antibody components for rapid immune-detection of AMI.(13) Similarly, additional anti-cTnI monoclonal antibodies presented in this study are equally beneficial to AMI patients in terms of rapid immunodiagnosis of AMI. These antibodies may be useful for different assay platforms designed to detect cTnI. Clinical correlation studies were also performed for the EIA kit formulated in this study and compared with that of Abbott’s AxSYM system. The correlation coefficient obtained from such a study with 110 AMI cases was 0.9018, which is considered to be satisfactory for clinical applications and fulfills the requirements or route standard performance by the US Drug and Food Administration (K023505, K050644). In conclusion, immunoassays designed with a combination of epitope-distinct anti-cTnI monoclonal antibodies recognizing the N-terminal half of cTnI yield reliable detection and greater sensitivity for cTnI in AMI patients. Therefore, these anti-cTnI monoclonal antibodies hold great potential in assisting healthcare workers in early diagnosis of AMI patients. Author Disclosure Statement

The authors have no financial interests to disclose.




1. Hartner KT, and Pette D: Fast and slow isoforms of troponin I and troponin C. Distribution in normal rabbit muscles and effects of chronic stimulation. Eur J Biochem 1990;188:261–267. 2. Vallins WJ, Brand NJ, Dabhade N, et al: Molecular cloning of human cardiac troponin I using polymerase chain reaction. FEBS Lett 1990;270:57–61. 3. Cummins B, Auckland ML, and Cummins P: Cardiacspecific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am Heart J 1987;113:1333–1344. 4. Wu AHB (Ed.). Cardiac Markers, 2nd ed. Human Press, Totawa, NJ, 2003. p. 467. 5. Katrukha AG, Bereznikova AV, Filatov VL, et al: Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem 1998;44:2433–2440. 6. Katrukha AG, Bereznikova AV, Esakova TV, et al: Troponin I is released in bloodstream of patients with acute myocardial infarction not in free form but as complex. Clin Chem 1997;43:1379–1385. 7. Wu AH, Feng YJ, Moore R, et al: Characterization of cardiac troponin subunit release into serum after acute myocardial infarction and comparison of assays for troponin T and I. American Association for Clinical Chemistry Subcommittee on cTnI Standardization. Clin Chem 1998;44:1198–1208. 8. Apple FS: Clinical and analytical standardization issues confronting cardiac troponin I. Clin Chem 1999;45:18–20. 9. Datta P, Foster K, and Dasqupta A: Comparison of immunoreactivity of five human cardiac troponin I assays toward free and complexed forms of the antigen: implications for assay discordance. Clin Chem 1999;45:2266–2269. 10. Shi Q, Ling M, Zhang X, et al: Degradation of cardiac troponin I in serum complicates comparisons of cardiac troponin I assays. Clin Chem 1999;45:1018–1025. 11. Diercks DB, Peacock WFt, Hollander JE, et al: Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in

12. 13.

14. 15.

16. 17.


early presenters to the emergency department with chest pain. Am Heart J 2012;163:74–80 e4. Keller T, Zeller T, Peetz D, et al: Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868–877. Lee C-YG, Whitman B, Chen J, Fung A, and Lin X: Monoclonal antibody-based immunoassays for reliable detection of human cardiac troponin I. J Clin Ligand Assay 2002;25:306–311. Lee C-YG, Huang Y-S, Huang C-H, Ping-C H, and Menge AC: Monoclonal antibodies to human sperm antigens. J Reprod Immunol 1982;4:173–181. Wilson M, and Nakane P: Recent developments in periodate method of conjugating horseradish peroxidase (HRPO) to antibodies. In: Immunofluorescence and Related Staining Techniques, Knapp W, Holbar K, and Wick G (Eds.). Elsevier/North-Holland Biochemical Press, Amsterdam, 1978. pp. 215–224. Go AS, Mozaffarian D, Roger VL, et al: Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation 2014;129:e28-e292. James S, Flodin M, Johnston N, Lindahl B, and Venge P: The antibody configurations of cardiac troponin I assays may determine their clinical performance. Clin Chem 2006;52:832–837. Dennis EA: Methods in Enzymology. Academic Press, San Diego, 1988.

Address correspondence to: Dr. Gregory Lee UBC Center for Reproductive Health 9117 Shaughnessy Street Vancouver, BC V6P 6R9 Canada E-mail: cyle[email protected] Received: November 7, 2014 Accepted: January 7, 2015

Monoclonal Antibodies Against Human Cardiac Troponin I for Immunoassays II.

Human cardiac troponin I (cTnI) is one of the most specific biomarkers for detection of acute myocardial infarction (AMI). To formulate immunoassay ki...
146KB Sizes 2 Downloads 9 Views